COVID-19 and myositis - unique challenges for patients

Area of Science:

• Rheumatology
• Immunology
• Public Health

Background:

• The COVID-19 pandemic significantly impacted healthcare systems globally.
• Long-term autoimmune conditions require continuous management and monitoring.
• Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting muscles.

Purpose of the Study:

• To assess the challenges faced by patients with idiopathic inflammatory myopathies (IIM) during the COVID-19 pandemic.
• To evaluate the pandemic's effects on disease control, medical care, and medication access for IIM patients.

Main Methods:

• An anonymized eSurvey was distributed to patients with IIM.
• The survey focused on disease control, continuity of care, drug procurement, and patient concerns.
• Data from 608 participants were analyzed.

Main Results:

• 32.1% of patients reported health problems due to the pandemic, with 52.3% needing more medication and 18% requiring hospitalization.
• Nearly 25% faced difficulties obtaining medications, and 35.2% experienced disruptions in physiotherapy.
• 26.1% had trouble contacting specialists, and 69.6% supported remote consultations for care continuity.

Conclusions:

• The COVID-19 pandemic negatively affected the continuity of medical care for many IIM patients.
• Disruptions in care, including medication access and therapy, raise concerns about potential long-term adverse outcomes.
• Maintaining consistent medical care is crucial for managing chronic autoimmune conditions like IIM.